摘要
目的探究在冠心病合并糖尿病患者中将沙格列汀进行应用对患者的血糖和心功能的影响效果。方法将该院2019年8月—2020年8月接受治疗的120例冠心病合并糖尿病患者,随机分为两组,对照组给予二甲双胍缓释片治疗,实验组则给予DPP-4抑制剂沙格列汀治疗,每组60例,对两组患者的治疗效果进行比较观察。结果两组患者治疗前的心功能和血糖指标均差异无统计学意义(P>0.05),在给予治疗干预后,各项指标和功能均发生改变,但是实验组的改变效果更显著,组间数据差异较大,而且两组患者的不良反应发生率分别为5.00%和18.33%,实验组的发生率更低,数据差异有统计学意义(P<0.05)。结论在冠心病合并糖尿病患者中将沙格列汀治疗方法进行应用,其临床效果显著,可将患者的血糖进行降低,将患者心功能进行改善,临床意义显著。
Objective To explore the effect of saxagliptin on the blood glucose and cardiac function of patients with coronary heart disease and diabetes.Methods A total of 120 patients with coronary heart disease complicated with diabetes who were treated in the hospital from August 2019 to August 2020 were randomly divided into two groups:the control group was treated with metformin sustained release tablets,and the experimental group was treated with the DPP-4 inhibitor,shagliptin,with 60 patients in each group.The therapeutic effects of the two groups were compared and observed.Results There was no significant difference in cardiac function and blood glucose index between the two groups before treatment(P>0.05).After treatment intervention,various indexes and functions changed,but the effect of the changes in the experimental group was more significant,and the data between the groups were quite different.The incidence of adverse reactions of patients in the experimental group was 5.00%and 18.33%,respectively,the incidence of the experimental group was lower,and the difference was statistically significant(P<0.05).Conclusion The application of saxagliptin in patients with coronary heart disease and diabetes mellitus has significant clinical effects.It can reduce the patient's blood glucose and improve the patient's heart function,which has significant clinical significance.
作者
陈炜星
CHEN Wei-Xing(General Hospital of Minqing County,Fuzhou,Fujian Province,350800 China)
出处
《糖尿病新世界》
2020年第22期87-89,共3页
Diabetes New World Magazine
关键词
沙格列汀
冠心病合并糖尿病
血糖
心功能
影响效果
Saxagliptin
Coronary heart disease with diabetes
Blood glucose
Heart function
Effect
